Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

Clinicians analyze long-term efficacy data in psoriasis treatments, focusing on how they communicate and contextualize information about treatment duration to their patients.

EP: 1.Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

EP: 2.Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

EP: 3.Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

EP: 4.A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

EP: 5.Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

EP: 6.Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

EP: 7.TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

EP: 8.Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

EP: 9.Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

EP: 10.Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

EP: 11.Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

Now Viewing

EP: 12.Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

EP: 13.When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

EP: 14.Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP: 15.Available Psoriasis, Patient Involvement, and Holistic Treatment

Related Videos

Related Content

Advertisement

March 27th 2025

Patient and Physician Perspectives Assess Long-Term Impact of Tildrakizumab for Psoriasis

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

March 24th 2025

ESK-001: A Conversation with Jörn Drappa, MD, PhD, of Alumis on Breakthrough Data and the Future of Psoriasis Treatment

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

March 19th 2025

Post Hoc Analysis Highlights Zasocitinib’s Efficacy Across Patient Groups

March 14th 2025

Home Phototherapy Proves Effective and Preferred in LITE Study for Psoriasis Treatment

Related Content

Advertisement

March 27th 2025

Patient and Physician Perspectives Assess Long-Term Impact of Tildrakizumab for Psoriasis

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

March 24th 2025

ESK-001: A Conversation with Jörn Drappa, MD, PhD, of Alumis on Breakthrough Data and the Future of Psoriasis Treatment

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

March 19th 2025

Post Hoc Analysis Highlights Zasocitinib’s Efficacy Across Patient Groups

March 14th 2025

Home Phototherapy Proves Effective and Preferred in LITE Study for Psoriasis Treatment